Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition
| Autor: | Sheila Bingham, Mazda Jenab, H. B. Bueno-De-Mesquita, C. Travezea, Domenico Palli, H. Boeing, Eva Ardanaz, Antonia Trichopoulou, J. Linseisen, Elio Riboli, C. A. Gonzalez, María José Sánchez, Amalia Mattiello, Naomi E. Allen, Anne Tjønneland, Lambertus A. Kiemeney, Tobias Pischon, Rudolph Kaaks, J. R. Quirós, K-T Khaw, C. Navarro, Paul N. Appleby, D. Trichopoulos, Carlotta Sacerdote, Pamela Ferrari, Henning Grønbæk, S. Rinaldi, Lars Egevad, Nerea Larrañaga, Ruth C. Travis, Timothy J. Key, Andrew W. Roddam, Kim Overvad, Rosario Tumino, S. Rohrmann, Franco Berrino, N. F. Johnsen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Epidemiology Enzyme-Linked Immunosorbent Assay Aetiology screening and detection [ONCOL 5] Molecular epidemiology [NCEBP 1] Prostate cancer Translational research [ONCOL 3] Interventional oncology [UMCN 1.5] Risk Factors Internal medicine medicine Humans Risk factor Insulin-Like Growth Factor I Aged Neoplasm Staging Aged 80 and over Hereditary cancer and cancer-related syndromes [ONCOL 1] business.industry Cancer Prostatic Neoplasms Odds ratio Middle Aged medicine.disease Confidence interval European Prospective Investigation into Cancer and Nutrition Endocrinology Insulin-Like Growth Factor Binding Protein 3 Case-Control Studies Functional Imaging [UMCN 1.1] business Cohort study |
| Zdroj: | Cancer Epidemiology, Biomarkers & Prevention, 16, 1121-7 Cancer Epidemiology, Biomarkers & Prevention, 16, 6, pp. 1121-7 |
| ISSN: | 1055-9965 |
| Popis: | Background: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer. Methods: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression. Results: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; Ptrend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; Ptrend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; Ptrend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; Ptrend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; Ptrend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; Ptrend = 0.11) for IGF-I adjusted for IGFBP-3. Conclusions: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed. (Cancer Epidemiol Biomarkers Prev 2007;16(6):1121–7) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|